<HashMap><database>biostudies-literature</database><scores><citationCount>0</citationCount><reanalysisCount>0</reanalysisCount><viewCount>46</viewCount><searchCount>0</searchCount></scores><additional><submitter>Hiraiwa M</submitter><funding>MEXT | Japan Society for the Promotion of Science</funding><funding>MEXT | Japan Society for the Promotion of Science (JSPS)</funding><pagination>22</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8752672</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>5(1)</volume><pubmed_abstract>Glioma stem cells (GSCs) contribute to the pathogenesis of glioblastoma, the most malignant form of glioma. The implication and underlying mechanisms of SMAD specific E3 ubiquitin protein ligase 2 (SMURF2) on the GSC phenotypes remain unknown. We previously demonstrated that SMURF2 phosphorylation at Thr&lt;sup>249&lt;/sup> (SMURF2&lt;sup>Thr249&lt;/sup>) activates its E3 ubiquitin ligase activity. Here, we demonstrate that SMURF2&lt;sup>Thr249&lt;/sup> phosphorylation plays an essential role in maintaining GSC stemness and tumorigenicity. SMURF2 silencing augmented the self-renewal potential and tumorigenicity of patient-derived GSCs. The SMURF2&lt;sup>Thr249&lt;/sup> phosphorylation level was low in human glioblastoma pathology specimens. Introduction of the SMURF2&lt;sup>T249A&lt;/sup> mutant resulted in increased stemness and tumorigenicity of GSCs, recapitulating the SMURF2 silencing. Moreover, the inactivation of SMURF2&lt;sup>Thr249&lt;/sup> phosphorylation increases TGF-β receptor (TGFBR) protein stability. Indeed, TGFBR1 knockdown markedly counteracted the GSC phenotypes by SMURF2&lt;sup>T249A&lt;/sup> mutant. These findings highlight the importance of SMURF2&lt;sup>Thr249&lt;/sup> phosphorylation in maintaining GSC phenotypes, thereby demonstrating a potential target for GSC-directed therapy.</pubmed_abstract><journal>Communications biology</journal><pubmed_title>SMURF2 phosphorylation at Thr249 modifies glioma stemness and tumorigenicity by regulating TGF-β receptor stability.</pubmed_title><pmcid>PMC8752672</pmcid><funding_grant_id>20H03407</funding_grant_id><pubmed_authors>Park G</pubmed_authors><pubmed_authors>Hirao A</pubmed_authors><pubmed_authors>Hinoi E</pubmed_authors><pubmed_authors>Tokumura K</pubmed_authors><pubmed_authors>Sabit H</pubmed_authors><pubmed_authors>Nakada M</pubmed_authors><pubmed_authors>Fukasawa K</pubmed_authors><pubmed_authors>Kobayashi M</pubmed_authors><pubmed_authors>Suzuki A</pubmed_authors><pubmed_authors>Kaneda K</pubmed_authors><pubmed_authors>Hiraiwa M</pubmed_authors><pubmed_authors>Iezaki T</pubmed_authors><pubmed_authors>Murata M</pubmed_authors><pubmed_authors>Todo T</pubmed_authors><pubmed_authors>Horie T</pubmed_authors><pubmed_authors>Iwahashi S</pubmed_authors><view_count>46</view_count></additional><is_claimable>false</is_claimable><name>SMURF2 phosphorylation at Thr249 modifies glioma stemness and tumorigenicity by regulating TGF-β receptor stability.</name><description>Glioma stem cells (GSCs) contribute to the pathogenesis of glioblastoma, the most malignant form of glioma. The implication and underlying mechanisms of SMAD specific E3 ubiquitin protein ligase 2 (SMURF2) on the GSC phenotypes remain unknown. We previously demonstrated that SMURF2 phosphorylation at Thr&lt;sup>249&lt;/sup> (SMURF2&lt;sup>Thr249&lt;/sup>) activates its E3 ubiquitin ligase activity. Here, we demonstrate that SMURF2&lt;sup>Thr249&lt;/sup> phosphorylation plays an essential role in maintaining GSC stemness and tumorigenicity. SMURF2 silencing augmented the self-renewal potential and tumorigenicity of patient-derived GSCs. The SMURF2&lt;sup>Thr249&lt;/sup> phosphorylation level was low in human glioblastoma pathology specimens. Introduction of the SMURF2&lt;sup>T249A&lt;/sup> mutant resulted in increased stemness and tumorigenicity of GSCs, recapitulating the SMURF2 silencing. Moreover, the inactivation of SMURF2&lt;sup>Thr249&lt;/sup> phosphorylation increases TGF-β receptor (TGFBR) protein stability. Indeed, TGFBR1 knockdown markedly counteracted the GSC phenotypes by SMURF2&lt;sup>T249A&lt;/sup> mutant. These findings highlight the importance of SMURF2&lt;sup>Thr249&lt;/sup> phosphorylation in maintaining GSC phenotypes, thereby demonstrating a potential target for GSC-directed therapy.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jan</publication><modification>2024-02-14T21:41:11.533Z</modification><creation>2022-02-11T15:28:54.759Z</creation></dates><accession>S-EPMC8752672</accession><cross_references><pubmed>35017630</pubmed><doi>10.1038/s42003-021-02950-0</doi></cross_references></HashMap>